IRF5 and systemic lupus erythematosus: Independently, we developed another series of peptide inhibitors that are cell permeable, directly bind to full-length endogenous IRF5, and inhibit the development of murine lupus in vivo [(112); U.S. Patent No WO2017044855A2].